CHROMR has also been implicated in elevated risk for stomach adenocarcinoma (Luo et al., 2022), lung adenocarcinoma (Bai et al., 2022), increased resistance to chemotherapy in Lymphoma (Wang et al., 2022), but also in antiviral response to Influenza and COVID-19 infections (van Solingen et al., 2022) and autoimmune disease, such as multiple sclerosis (Teimuri et al., 2018). Here, CHROMR is linked to autoimmune disease.